Using the Cecal Ligation and Puncture Model of Sepsis to Induce Rats to Multiple Organ Dysfunction
Carregando...
Citações na Scopus
3
Tipo de produção
article
Data de publicação
2021
Título da Revista
ISSN da Revista
Título do Volume
Editora
BIO-PROTOCOL
Autores
CAPCHA, Jose Manuel Condor
MOREIRA, Roberto S.
Citação
BIO-PROTOCOL, v.11, n.7, article ID e3979, 9p, 2021
Resumo
Sepsis is a dysregulated hyperinflammatory disease caused by infection. Sepsis leads to multiple organ dysfunction syndrome (MODS), which is associated with high rates of mortality. The cecal ligation and puncture (CLP) model has been widely used in animals and has become the gold-standard method of replicating features of sepsis in humans. Despite several studies and modified CLP protocols, there are still open questions regarding the multifactorial determinants of its reproducibility and medical significance. In our protocol, which is also aimed at mimicking the sepsis observed in clinical practice, male Wistar rats are submitted to CLP with adequate fluid resuscitation (0.15 M NaCl, 25 ml/kg BW i.p.) immediately after surgery. At 6 h after CLP, additional fluid therapy (0.15 M NaCl, 25 ml/kg BW s.c.) and antibiotic therapy with imipenem-cilastatin (single dose of 14 mg/kg BW s.c.) are administered. The timing of the fluid and antibiotic therapy correspond to the initial care given when patients are admitted to the intensive care unit. This model of sepsis provides a useful platform for simulating human sepsis and could lay the groundwork for the development of new treatments.
Palavras-chave
Sepsis, Rats, Cecal ligation and puncture (CLP), Organ dysfunction, Animal Model, Acute Kidney Injury
Referências
- BAKER CC, 1983, SURGERY, V94, P331
- BONE RC, 1992, CRIT CARE MED, V20, P864, DOI 10.1097/00003246-199206000-00025
- Capcha JMC, 2020, AM J PHYSIOL-REG I, V318, pR135, DOI 10.1152/ajpregu.00098.2018
- Condor JM, 2016, STEM CELL TRANSL MED, V5, P1048, DOI 10.5966/sctm.2015-0138
- Fink MP, 2014, VIRULENCE, V5, P143, DOI 10.4161/viru.26083
- Hotchkiss RS, 2013, NAT REV IMMUNOL, V13, P862, DOI 10.1038/nri3552
- Institute for Laboratory Animal Research, 2011, GUIDE CARE USE LAB A, V8
- Kellum JA, 2019, NEPHRON, V143, P174, DOI 10.1159/000500167
- Moreira RS, 2014, AM J PHYSIOL-REG I, V307, pR514, DOI 10.1152/ajpregu.00445.2013
- Parker SJ, 2001, BRIT J SURG, V88, P22, DOI 10.1046/j.1365-2168.2001.01632.x
- Rello J, 2017, ADV THER, V34, P2393, DOI 10.1007/s12325-017-0622-8
- Rodrigues CE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029893
- Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287
- Singleton KD, 2003, EUR SURG RES, V35, P486, DOI 10.1159/000073387
- Torio C. M., 2016, HEALTHCARE COST UTIL
- WICHTERMAN KA, 1980, J SURG RES, V29, P189, DOI 10.1016/0022-4804(80)90037-2